001 001
  1. A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years
  2. Association of radiation dose to cardiac substructures with major ischaemic events following breast cancer radiotherapy
  3. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses
  4. Clinicopathological characteristics and treatment outcomes of luminal B1 breast cancer in Taiwan
  5. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-postive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital
  6. Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trail and the perspective of Taiwan’s National Health Insurance Administration
  7. Carboplatin and vinblastine monthly in the optic pathway and hypothalamic gliomas: A retrospective analysis in a single institute
  8. Early prediction of platelet recovery with immature platelet fraction in patients receiving hematopoietic stem cell transplantation
  9. Effect of co-medications and potential risk factors of high-dose methotrexate-mediated acute hepatotoxicity in patients with osteosarcoma
  10. FAS receptor regulates NOTCH activity through ERK-JAG1 axis activation and controls oral cancer stemness ability and pulmonary metastatasis
  11. Editorial: Metabolism-based omics integrations, biosensors, and molecular mechanisms in human cancers
  12. Growth differentiation factor 15 induces cisplatin resistance through upregulation of xCT expression and glutathione synthesis in gastric cancer
  13. Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients
  14. Integrated stress response-upregulated mitochondrial SLC1 A5var enhances glucose dependency in human breast cancer cells in vitro
  15. Impact of previous S-1treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
  16. Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
  17. Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer
  18. Mitochondrial dysfunction decreases cisplatin sensitivity in gastric cancer cells through upregulation of integrated stress response and mitokine GDF15
  19. Prognostic factors in patients with bone marrow hemophagocytosis and its association with hematologic malignancies
  20. Predicting Breast Cancer GENE Expression Signature by Applying Deep Convolutional Neural Networks From Unannotated Pathological Images
  21. Prediction of Breast Cancer Recurrence Using a Deep Convolutional Neural Network Without Region-of-Interest Labeling
  22. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation
  23. Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine
  24. Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway 
  25. The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis
  26. The influence of hospital volume and physician volume on early mortality in acute promyelocytic leukemia patients
  27. The impact of ZTE-based MR attenuation correction compared to CT-AC in 18F-FBPA PET before boron neutron capture therapy
  28. Targeted Sequencing of Taiwanese Breast Cancer with Risk Stratification by the Concurrent Genes Signature: A Feasibility Study 
  29. Identifying breast cancer risk factors and evaluating biennial mammography screening efficacy using big data analysis in Taiwan
  30. Survival outcomes in trial defined high-risk hormone receptor-positive/human epidermal growth factor receptor II-negative early breast cancer: impact of adjuvant chemotherapy